Education
About Us
Working with TipRanks
Follow Us
Amylyx Pharmaceuticals, Inc. (AMLX)
:AMLX
Total Valuation
Amylyx Pharmaceuticals Inc has a market cap or net worth of $309.22M. The enterprise value is -$11.21M.
Market Cap$309.22M
Enterprise Value-$11.21M
Share Statistics
Amylyx Pharmaceuticals Inc has 88.60M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding88.60M
Owened by Insiders14.16%
Owened by Instutions26.93%
Financial Efficiency
Amylyx Pharmaceuticals Inc’s return on equity (ROE) is -1.83 and return on invested capital (ROIC) is -188.50%.
Return on Equity (ROE)-183.14%
Return on Assets (ROA)-155.83%
Return on Invested Capital (ROIC)-188.50%
Return on Capital Employed (ROCE)-190.48%
Revenue Per Employee$710,333.341
Profits Per Employee-$2,453,195.122
Employee Count123
Asset Turnover0.45
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Amylyx Pharmaceuticals Inc is -0.85. Amylyx Pharmaceuticals Inc’s PEG ratio is <0.01.
PE Ratio-0.85
PS Ratio2.95
PB Ratio1.56
Price to Fair Value1.56
Price to FCF-1.53
Price to Operating Cash Flow-1.54
PEG Ratio<0.01
Income Statement
In the last 12 months, Amylyx Pharmaceuticals Inc had revenue of $87.37M and earned -$301.74M in profits. Earnings per share was -$4.44.
Revenue$87.37M
Gross Profit-$37.78M
Operating Income-$291.88M
Pretax Income-$302.14M
Net Income-$301.74M
EBITDA-254.77M
Earnings Per Share (EPS)-4.44
Cash Flow
In the last 12 months, operating cash flow was -$167.65M and capital expenditures -$157.00K, giving a free cash flow of -$167.80M billion.
Operating Cash Flow-$167.65M
Free Cash Flow-$167.80M
Free Cash Flow per Share-$1.89
Dividends & Yields
Amylyx Pharmaceuticals Inc pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-65.15%
Earnings Yield-117.15%
Stock Price Statistics
Beta1.39
52-Week Price Change76.33%
50-Day Moving Average3.54
200-Day Moving Average3.48
Relative Strength Index (RSI)42.11
Average Volume (3m)841.01K
Important Dates
Amylyx Pharmaceuticals Inc upcoming earnings date is May 8, 2025, After Close.
Last Earnings DateMar 4, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
Amylyx Pharmaceuticals Inc as a current ratio of 6.67, with Debt / Equity ratio of 0.01
Current Ratio6.67
Quick Ratio6.67
Debt to Market Cap<0.01
Net Debt to EBITDA0.26
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Amylyx Pharmaceuticals Inc has paid -$393.00K in taxes.
Income Tax-$393.00K
Effective Tax Rate0.13%
Enterprise Valuation
Amylyx Pharmaceuticals Inc EV to EBITDA ratio is -0.63, with an EV/FCF ratio of -1.09.
EV to Sales2.08
EV to EBITDA-0.63
EV to Free Cash Flow-1.09
EV to Operating Cash Flow-1.09
Balance Sheet
Amylyx Pharmaceuticals Inc has $176.50M in cash and marketable securities with $1.98M in debt, giving a net cash position of -$174.52M billion.
Cash & Marketable Securities$176.50M
Total Debt$1.98M
Net Cash-$174.52M
Net Cash Per Share-$1.97
Tangible Book Value Per Share$2.42
Margins
Gross margin is 51.75%, with operating margin of -360.22%, and net profit margin of -345.36%.
Gross Margin51.75%
Operating Margin-360.22%
Pretax Margin-345.81%
Net Profit Margin-345.36%
EBITDA Margin-333.03%
EBIT Margin-334.07%
Analyst Forecast
The average price target for Amylyx Pharmaceuticals Inc is $8.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$8.25
Price Target Upside136.39%
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast-77.06%
EPS Growth Forecast-705.82%